845973-40-2

Basic information

• Product Name: 1-Piperazinecarboxylic acid, 2-[(1S,2S)-2-[bis(phenylmethyl)amino]-3-(3,5-difluorophenyl)-1-hydroxy propyl]-3-oxo-4-(phenylmethyl)-6-(2-propenyl)-, 1,1-dimethylethyl ester, (6S)-
• CAS NO: 845973-40-2
• Molecular Formula: C42H47F2N3O4
• Molecular Weight: 695.85
• Mol File: 845973-40-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-Piperazinecarboxylic acid, 2-[(1S,2S)-2-[bis(phenylmethyl)amino]-3-(3,5-difluorophenyl)-1-hydroxy propyl]-3-oxo-4-(phenylmethyl)-6-(2-propenyl)-, 1,1-dimethylethyl ester, (6S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinecarboxylic acid, 2-[(1S,2S)-2-[bis(phenylmethyl)amino]-3-(3,5-difluorophenyl)-1-hydroxy propyl]-3-oxo-4-(phenylmethyl)-6-(2-propenyl)-, 1,1-dimethylethyl ester, (6S)-(845973-40-2)
• EPA Substance Registry System: 1-Piperazinecarboxylic acid, 2-[(1S,2S)-2-[bis(phenylmethyl)amino]-3-(3,5-difluorophenyl)-1-hydroxy propyl]-3-oxo-4-(phenylmethyl)-6-(2-propenyl)-, 1,1-dimethylethyl ester, (6S)-(845973-40-2)

Safety Data

• Hazardous Substances Data: 845973-40-2(Hazardous Substances Data)

Upstream product

• 205445-52-9 (2S)-2-[(tert-butoxycarbonyl)amino]-3-(3,5-difluorophenyl)propanoic acid 
• 100-46-9 benzylamine 
• 95107-99-6 tert-butyl (S)-(1-oxopent-4-en-2-yl)carbamate 
• 100-39-0 benzyl bromide 
• 845973-37-7 C₁₇H₂₆N₂O₂ 
• 845543-59-1 C₂₄H₂₃F₂NO₂ 
• 845543-60-4 2-dibenzylamino-3-(3,5-difluoro-phenyl)-propan-1-ol 
• 473567-47-4 methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(3,5-difluorophenyl)propanoate 
• 845543-61-5 (S)-N,N-dibenzyl-3,5-difluorophenyl-alaninal 
• 845973-39-9 C₁₉H₂₆N₂O₃ 

Relevant articles and documents

CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R is-C(O)-N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer’s disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, and N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.